Fig. 3: Efficacy of EGT710 in a mouse model of SARS-CoV-2 infection. | npj Drug Discovery

Fig. 3: Efficacy of EGT710 in a mouse model of SARS-CoV-2 infection.

From: Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitor

Fig. 3

Balb/c mice were intranasally infected with 104 PFU mouse-adapted SARS-CoV-2 strain CMA4. Oral dosing was initiated immediately after infection, and mice were dosed twice daily (BID) for 2 days. Two days after infection, right lung lobes were collected for plaque assay or qRT-PCR. Viral titers A and RNA copies B) in mouse lungs two days post-infection after treatment with EGT710. C Unbound concentration of EGT710 in uninfected Balb/c mice following a single oral dose of either 1 mg/kg or 10 mg/kg. Dotted line indicates the unbound EC90 = 63.8 nM (EC90,assay = 65.6 nM, adjusted based on 2.82 % protein binding of EGT710 in the dNHBE media (Table 1)). Figures generated using GraphPad Prism software.

Back to article page